ClinicalTrials.gg
RecruitingNCT06939088DUALPSYCHIATRYUpdated Feb 10, 2026

Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder

A Phase 2 interventional study of Tirzepatide and Placebo in Alcohol Use Disorder, Alcohol Abuse/Dependence and Alcohol Dependence, sponsored by Anders Fink-Jensen, MD, DMSci. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Anders Fink-Jensen, MD, DMSci · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Alcoholism with a site in Denmark — 7 open to participants now, 11 under way, none of them phase 3. Alcoholism · Denmark.

Planned enrollment
16th of 29
108 · median 113
Started
2025
with 3 others
Phase 2
7 of 29
1 open now
Primary completion
2028-08
later than 8 of 10 live
Registered
27th of 29
by date
Lead sponsor
6 of 29
Anders Fink-Jensen, MD, DMSci

Among the 29 studies in Alcoholism with a site in Denmark, this one is the 16th largest by planned enrollment, is one of 4 that started in 2025, is one of 7 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 27th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

7 of the 29 studies in Alcoholism with a site in Denmark are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Alcoholism with a site in Denmark, or all of them as a file.
02

Study summary

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for the treatment of type 2 diabetes and obesity, have shown promise as a novel treatment for alcohol use disorder (AUD). This study aims to investigate whether the Glucose-dependent Insulinotropic Polypeptide/GLP-1RA tirzepatide will reduce alcohol consumption in patients with a dual diagnosis of AUD and schizophrenia, a population in dire need of improved treatment options. To further investigate the neurobiological underpinnings of a potential dampening effect on alcohol consumption, functional magnetic resonance imaging (fMRI) brain scans will be applied.

The key anticipated outcomes include:

  • decreased alcohol consumption and
  • reduced alcohol cue-induced brain activity in the GIP/GLP-1-treated patient group compared with the placebo group. To the best of the investigators knowledge, this has never been examined before.
Read the detailed description

The study is a randomised (1:1), double-blinded, placebo-controlled clinical trial including 26 weeks of treatment investigating whether tirzepatide vs placebo can reduce the number of heavy drinking days in patients with comorbid diagnoses of schizophrenia and AUD. The primary endpoint will be evaluated after 16 weeks of treatment. The study will conclude after a post-intervention follow-up 14 weeks after last treatment at week 40 of the study.

108 participants will be included. Alcohol consumption and secondary endpoints will be assessed at weeks 0, 4, 8, 12, 16, 20, 26, and 40, and all patients will be offered 6 sessions of supportive therapy, while participating in the study.

The randomisation and administration of the weekly injections (tirzepatide/placebo) will be administered by an unblinded staff not involved in other trial activities. All patients will be blindfolded when receiving the injections. Eligible patients (n=50) will have an fMRI brain scan performed at baseline and in week 16. Blood tests for safety measures and secondary endpoint-measures will be performed at weeks 0, 16, 26, and 40.

03

Conditions studied

  • Alcohol Use Disorder
  • Alcohol Abuse/Dependence
  • Alcohol Dependence
  • Alcoholism
  • Schizophrenia Disorders
  • Schizophrenia and Disorders With Psychotic Features
  • Schizophrenia and Schizophrenia Spectrum Psychosis
  • Schizophrenia

Keywords

  • GLP-1
  • Glucagon-like peptide 1
  • fMRI
  • GIP
  • Glucose-dependent Insulinotropic Polypeptide
  • Tirzepatide
  • Mounjaro(R)
  • schizophrenia
  • alcohol
  • alcohol use disorder
  • dual diagnosis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • : The patient must provide both oral and written informed consent.
  • Diagnosis:

    • Diagnosed with alcohol dependence according to the International Classification of Diseases, 10th Edition (ICD-10), and alcohol use disorder as per the , Fifth Edition (DSM-5).
    • Diagnosed with schizophrenia spectrum disorder according to ICD-10 and DSM-5
  • AUDIT Score: Alcohol Use Disorder Identification Test (AUDIT) score greater than 15.
  • (BMI): BMI of 23 kg/m² or higher.
  • Age Range: Between 18 and 70 years old (inclusive).
  • Heavy Alcohol Consumption: Defined as 4 or more heavy drinking days within a consecutive 21-day period during the 28 days preceding the baseline evaluation. The 21-day period will be selected based on the largest total alcohol consumption and the greatest number of heavy drinking days within the 28-day timeframe. This will be assessed using the Timeline Followback (TLFB) method. Heavy drinking days are defined as days with an alcohol intake of 4 or more units (48 g of alcohol) for women and 5 or more units (60 g of alcohol) for men.

Exclusion criteria

Exclusion Criteria:

  • Intellectual Disability: individuals with a diagnosis of intellectual disability.
  • Acute Psychosis: Acute exacerbation of psychosis, as indicated by a score of 6 or 7 on the Clinical Global Impression-Severity (CGI-S) scale.
  • Coercive Measures: Current use of coercive measures, which includes individuals sentenced to treatment ('dom til behandling').
  • Suicidal Behaviour: Evidence of current severe suicidal behaviour, as assessed by the investigator during clinical evaluation.
  • History of Severe Alcohol Withdrawal: History of delirium tremens or alcohol withdrawal seizures.
  • Severe Withdrawal Symptoms: Clinical Institute Withdrawal Assessment of Alcohol Scale, revised (CIWA-Ar) score greater than 9 at baseline examination.
  • Severe Neurological Conditions: Presence of severe neurological diseases, including severe traumatic brain injury.
  • Diabetes: Type 1 or 2 diabetes
  • Pregnant or Potentially Pregnant Women: who are pregnant, breastfeeding, intend to become pregnant within the next 6 months (including 16 weeks of treatment plus two months after discontinuation of semaglutide), or are not using a highly effective method throughout the study period. Highly effective methods include combined hormonal contraception (oral, intravaginal, transdermal), progestogen-only hormonal contraception (oral, injectable, implantable), intrauterine device (IUD), intrauterine system (IUS), bilateral tubal occlusion, vasectomised partner, or sexual abstinence. WOCBP with a measured serum human chorionic gonadotropin (hCG) level greater than 3 U/L at inclusion will also be excluded.
  • Liver Function: Impaired hepatic function, defined as liver transaminases greater than three times the .
  • Renal Function: Impaired renal function, indicated by an estimated (eGFR) below 50 mL/min and/or plasma creatinine above 150 μmol/L.
  • Pancreatic Function: History of acute or chronic pancreatitis or amylase levels more than twice the upper limit of normal.
  • Thyroid Conditions: Previous medullary thyroid carcinoma (MTC) or a family history of MTC and/or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Cardiac Issues: Decompensated heart failure ( class III or IV), unstable angina pectoris, or myocardial infarction within the past 12 months.
  • Uncontrolled Hypertension: Systolic blood pressure above 180 mmHg or diastolic blood pressure above 110 mmHg.
  • Alcohol Use Disorder Medication: Use of medications for alcohol use disorder (e.g., disulfiram, naltrexone, acamprosate, nalmefene) within the 28 days prior to inclusion as recorded in the Timeline Followback (TLFB) schedule.
  • Drugs: Receipt of any investigational drug within the past three months.
  • Weight-Lowering Medications: Use of other weight-lowering pharmacotherapy in the past three months.
  • Allergic Reactions: to the active substance or any of the .
  • Language Barriers: Inability to speak and/or understand Danish.
  • Other Conditions: Any other condition that, in the investigator\'s opinion, may interfere with participation in the trial.

For the subgroup of participants undergoing brain scans:

  • MRI : any contraindications for MRI (e.g., magnetic implants, pacemaker, claustrophobia).
  • Benzodiazepine Use: Intermittent use of benzodiazepines within 12 days prior to the scanning session is not allowed. However, regular use of a stable dose of benzodiazepines is permitted.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Tirzepatide

    Tirzepatide once-weekly s.c.titrated to a maximum dose of 15 mg

    Drug: Tirzepatide

  • Placebo comparator
    Placebo

    Saline s.c. once-weekly

    Drug: Placebo

Interventions

  • Once weekly injections s.c. with tirzepatide (Mounjaro(R))

    Also known as: Mounjaro

  • DrugPlacebo

    Once weekly injections s.c. with placebo (BD Posiflush)

    Also known as: BD Posiflush (saline)

06

What researchers measure

Primary outcomes

  1. Change in heavy drinking days

    The primary endpoint will be a change in alcohol consumption, measured as a per cent change in heavy drinking days after 16 weeks of treatment with tirzepatide or placebo, adjusted for the value at baseline (percentage points). Heavy drinking days will be registered using the Timeline-Follow-Back (TLFB) method including the last 21 consecutive days with the largest total alcohol intake and the greatest number of heavy drinking days within the 28 days preceding the evaluation. A heavy drinking day is defined as more than 60/48 grams (men/women) of alcohol in one day.

    Time frame: From baseline to 16 weeks of treatment

Secondary outcomes

  1. Heavy drinking days

    Change in heavy drinking days measured using the TLFB method.

    Time frame: From baseline to 26 weeks of treatment and 14 weeks post-intervention

  2. Total alcohol consumption

    Change in total alcohol consumption measured using the TLFB method.

    Time frame: From baseline to 16 and 26 weeks of treatment and 14 weeks post-intervention

  3. Days without alcohol consumption

    Change in number of days without alcohol measured using the TLFB method.

    Time frame: From baseline to 16 and 26 weeks of treatment and 14 weeks post-intervention

  4. World Health Organization (WHO) Risk Levels of Alcohol Consumption

    Change in WHO alcohol risk level measured using the TLFB method.

    Time frame: From baseline to 16 and 26 weeks of treatment and 14 weeks post-intervention

  5. Penn Alcohol Craving Scale (PACS) score

    Change in Penn Alcohol Craving Scale (PACS) score. Minimum score = 0, maximum score =30. A high score means a worse outcome.

    Time frame: From baseline to 16 and 26 weeks of treatment

  6. Alcohol Use Disorder Identification Test (AUDIT) score

    Change in AUDIT score. Minimum score = 0, maximum score =40. A high score means a worse outcome.

    Time frame: From baseline to 16 and 26 weeks of treatment

  7. Drug Use Disorders Identification Test (DUDIT) score

    Change in DUDIT score. Minimum score = 0, maximum score =44. A high score means a worse outcome.

    Time frame: From baseline to 16 and 26 weeks of treatment

  8. Drug use frequency

    Change in drug use frequency measured using the drug use frequency section of the DUDIT-extended

    Time frame: From baseline to 16 and 26 weeks of treatment

  9. Preferred substance of use

    Change in preferred substance of use

    Time frame: From baseline to 16 and 26 weeks of treatment

  10. Biomarkers of cannabis exposure

    Changes in biomarkers of recent cannabis exposure (blood 11-hydroxy-delta 9-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH) levels)

    Time frame: From baseline to 16 and 26 weeks of treatment

  11. The Patient Health Questionnaire (PHQ-9)

    Changes in PHQ-9

    Time frame: From baseline to 16 and 26 weeks of treatment

  12. Fagerströms Test for Nicotine Dependence score

    Changes in smoking habits using the Fagerströms Test for Nicotine Dependence score

    Time frame: From baseline to 16 and 26 weeks of treatment

  13. Number of cigarettes smoked per day

    Changes in average number of cigarettes smoked per day

    Time frame: From baseline to 16 and 26 weeks of treatment

  14. Cotinine levels

    Change in blood cotinine levels

    Time frame: From baseline to 16 and 26 weeks of treatment

  15. Blood parameters

    Changes in blood parameters (GGT, ALAT, MCV)

    Time frame: From baseline to 16 and 26 weeks of treatment

  16. Liver fibrosis (FIB-4 score)

    Changes in FIB-4 score

    Time frame: From baseline to 26 weeks of treatment

  17. Blood phosphatidyl ethanol (PEth) levels

    Changes in PEth levels

    Time frame: From baseline to 16 and 26 weeks of treatment and 14 weeks post-intervention

  18. Glycaemic control parameters

    Changes in HbA1c levels

    Time frame: From baseline to 16 and 26 weeks of treatment and 14 weeks post-intervention

  19. Blood pressure

    Change in blood pressure

    Time frame: From baseline to 16 and 26 weeks of treatment

  20. Body weight

    Change in body weight

    Time frame: From baseline to 16 and 26 weeks of treatment and 14 weeks post-intervention

  21. Waist circumference

    Change in waist circumference

    Time frame: From baseline to 16 and 26 weeks of treatment

  22. fMRI alcohol cue-reactivity

    Changes in fMRI BOLD signals in response to alcohol cues in brain regions related to reward in a subgroup (n=50) of participants

    Time frame: From baseline to 16 weeks of treatment

  23. WHO-5 Subjective Well-Being Index

    Changes in quality of life measured using the World Health Organization-Five Well-Being Index (WHO-5)

    Time frame: From baseline to 26 weeks of treatment

  24. Global Assessment of Psychosocial Disability (GAPD)

    Changes in GAPD score

    Time frame: From baseline to 26 weeks of treatment

  25. Positive and Negative Syndrome Scale (PANSS-6)

    Changes in symptom severity of schizophrenia measured using PANSS-6

    Time frame: From baseline to 26 weeks of treatment

  26. Clinical Global Impression Severity Scale (CGI-S)

    Changes in CGI-S score

    Time frame: From baseline to 26 weeks of treatment

  27. Proteomics

    Change in proteomics

    Time frame: From baseline to 16 and 26 weeks of treatment

  28. Qualitative experience

    For a subgroup of participants (n=20), qualitative interviews will be performed after 16 weeks of treatment to evaluate qualitative differences in trial participation experiences between the intervention and placebo groups, which will be assessed as a secondary outcome.

    Time frame: From baseline to 16 weeks of treatment

Other outcomes

  1. Safety Outcome

    Suicidal ideation measured using the Columbia Suicide Severity Rating Scale (C-SSRS)

    Time frame: From baseline to 16 and 26 weeks of treatment

07

Study locations

2 of 2 sites recruiting
  • Department of Psychiatry, Aalborg University Hospital
    Aalborg, Denmark 9000, Denmark
    Recruiting
    • René E Nielsen, Chief Physician, Professor · Contactren@rn.dk · +45 28 72 29 62
  • Psychiatric Center Copenhagen, Frederiksberg Hospital
    Frederiksberg, Denmark 2100, Denmark
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — IPD will be shared upon reasonable relevant requests, e.g. for meta-analyses or independent validations. IPD will be shared anonymized or de-identified to protect participants' privacy and in accordance with relevant regulations (GDPR).

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Aug 2028, 38 months after the start.

Of 123 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 38 months is close to that.

Counting every sponsor, half of 135 studies reached it within 33 months; a quarter within 21 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
Apr 22, 2025
StartActual
May 5, 2025
Primary completionEst.
Aug 1, 2028
CompletionEst.
Dec 31, 2028
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06939088
Lead sponsor
Anders Fink-Jensen, MD, DMSci
Responsible party
Anders Fink-Jensen, MD, DMSci (Professor, MD, DMSc, Psychiatric Centre Rigshospitalet) — Sponsor-investigator
First posted
Apr 22, 2025
Start date
May 5, 2025
Primary completion
Aug 1, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Feb 10, 2026

Study contacts

Søren B Jensen, MD
Contact
soeren.broegger.jensen@regionh.dk
+45 60294963
Anders Fink-Jensen, MD, DMSc
Contact
anders.fink-jensen@regionh.dk
+45 22755843
Anders Fink-Jensen, MD, DMSc, Professor
principal investigator · Mental Healt h Service Centre Copenhagen , Frederiksberg Hospital, NP Lab

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion